Dr. Uttam Yashwant Patil, Ph D., is Chief Executive Officer of ABVC BioPharma, Inc. from June 21, 2023 and serves as its Interim Chief Financial Officer from July 2024. Dr. Patil has served as the Chief Op...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Eugene Jiang	Chairman & Chief Business Officer	9.4yrs	US$200.00k	8.16% $ 590.0k
Tsung-Shann Jiang	Chief Scientific Officer	5.8yrs	US$200.00k	3.55% $ 256.7k
Tsang Ming Jiang	Director	7.1yrs	geen gegevens	0.34% $ 24.8k
Norimi Sakamoto	Independent Director	7.1yrs	geen gegevens	0.34% $ 24.7k
Yen-Hsin Chou	Independent Director	7.1yrs	geen gegevens	0.34% $ 24.8k
Yoshinobu Odaira	Independent Director	5.8yrs	geen gegevens	0.47% $ 34.1k
Susanna Cunningham-Rundles	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Chang-Jen Jiang	Director	7.1yrs	geen gegevens	0.34% $ 24.7k
Che-Wei Hsu	Independent Director	2.6yrs	geen gegevens	0.34% $ 24.6k
Shuling Jiang	Director	2.6yrs	geen gegevens	7.12% $ 515.2k
Hsin-Hui Miao	Independent Director	2.5yrs	geen gegevens	0.39% $ 28.4k
Yu-Min Chung	Independent Director	2.4yrs	geen gegevens	0.34% $ 24.8k

5.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ABVC wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/31 00:38
Aandelenkoers aan het einde van de dag	2024/12/31 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

ABVC BioPharma, Inc. wordt gevolgd door 2 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Jason McCarthy	Maxim Group
Marla Marin	Zacks Small-Cap Research

ABVC BioPharma Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

Less than half of directors are independent

ABVC BioPharma, Inc. Announces Board Changes

Recent updates

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

ABVC BioPharma Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

ABVC BioPharma, Inc. announced delayed 10-Q filing

ABVC BioPharma, Inc., Annual General Meeting, Apr 16, 2024

ABVC BioPharma, Inc., Annual General Meeting, Apr 17, 2024

ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC

ABVC BioPharma, Inc., Annual General Meeting, Jan 16, 2024

ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma, Inc. announced delayed 10-Q filing

Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study

ABVC BioPharma Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $1.75 million.

ABVC BioPharma, Inc. announced that it expects to receive $1.75 million in funding

Nasdaq Grants ABVC Biopharma an Extension to Comply with Listing Rule 5550(b)(1)

ABVC Biopharma, Inc. Appoints Dr. Uttam Yashwant Patil as Chief Executive Officer

ABVC BioPharma Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders' Equity Requirement

ABVC BioPharma, Inc. Announces Vitargus®? Phase II Study Receives Ethical Approval At Sydney Eye Hospital in Australia

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.20 loss in 1Q 2022)

ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt

ABVC BioPharma Receives an Additional 180 Days, Until August 14, 2023, to Comply with Rule 5550(a)(2)

Abvc Biopharma Abv-1505 Adhd Phase Iia Results Presented At 2023 Apsard Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma, Inc. Receives Thai FDA Approval for Phase II Vitargus Study Protocol

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder

ABVC BioPharma, Inc. Announces That Cedars-Sinai Medical Center Institutional Review Board (IRB) Approves Institution Joining the Phase I Study of ABV-1601

ABVC BioPharma, Inc. Announces Vitargus(R) Phase II Study Plan Approved by Hrec in Australia

Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute

Abvc Biopharma, Inc. Provides Adhd Phase Ii Part 2 Clinical Study Update and Announces Ucsf Institutional Review Board Approval

ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug

ABVC BioPharma Receives Non-Compliance Letter from Nasdaq

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M

ABVC BioPharma, Inc. Provides Vitargus Update

ABVC BioPharma, Inc. Announces Board Changes

ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial

ABVC BioPharma, Inc. Announces the Vitargus® Phase II Clinical Study Protocol Approval by the Central Research Ethics Committee (CREC) of the National Research Council of Thailand

Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute

ABVC BioPharma, Inc. Submitts Vitargus(R) Phase II Study Plan to Australia HREC

Abvc Biopharma, Inc. Appoints Ms. Hsin-Hui Miao to its Board

ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study

ABVC BioPharma, Inc. Announces Board Elections

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ABVC BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $4.22 million.

ABVC BioPharma, Inc. Announces ADHD Phase II Part 2 Clinical Study First Subject

ABVC Biopharma Announces Streamlined Vitargus® Manufacturing Process

Insufficient new directors

ABVC BioPharma, Inc. Announces Vitargus Phase II Clinical Study Investigator Meeting

Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

ABVC BioPharma, Inc. Selects Additional Vitargus Phase II Study Sites

Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?

High number of new directors

Third quarter 2021 earnings released: US$0.067 loss per share (vs US$0.095 loss in 3Q 2020)

High number of new directors

High number of new directors

High number of new directors

ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study

High number of new directors

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Second quarter 2021 earnings released: US$0.081 loss per share (vs US$0.095 loss in 2Q 2020)